JP2015512384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512384A5 JP2015512384A5 JP2015501614A JP2015501614A JP2015512384A5 JP 2015512384 A5 JP2015512384 A5 JP 2015512384A5 JP 2015501614 A JP2015501614 A JP 2015501614A JP 2015501614 A JP2015501614 A JP 2015501614A JP 2015512384 A5 JP2015512384 A5 JP 2015512384A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- treatment
- acid sequence
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 27
- 238000011282 treatment Methods 0.000 claims 21
- 150000007523 nucleic acids Chemical group 0.000 claims 16
- 230000002265 prevention Effects 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 208000035143 Bacterial infection Diseases 0.000 claims 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims 8
- 241001515965 unidentified phage Species 0.000 claims 8
- 241000588626 Acinetobacter baumannii Species 0.000 claims 7
- 206010060803 Diabetic foot infection Diseases 0.000 claims 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 7
- 230000000844 anti-bacterial effect Effects 0.000 claims 6
- 241000191967 Staphylococcus aureus Species 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 238000011301 standard therapy Methods 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000000845 anti-microbial effect Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims 2
- 206010040943 Skin Ulcer Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000002744 extracellular matrix Anatomy 0.000 claims 2
- 238000009256 replacement therapy Methods 0.000 claims 2
- 231100000019 skin ulcer Toxicity 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 201000000297 Erysipelas Diseases 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 239000002313 adhesive film Substances 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 238000001804 debridement Methods 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000416 hydrocolloid Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 238000002639 hyperbaric oxygen therapy Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612531P | 2012-03-19 | 2012-03-19 | |
| US61/612,531 | 2012-03-19 | ||
| PCT/PT2013/000016 WO2013141730A1 (en) | 2012-03-19 | 2013-03-19 | Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512384A JP2015512384A (ja) | 2015-04-27 |
| JP2015512384A5 true JP2015512384A5 (enExample) | 2016-05-19 |
| JP6186427B2 JP6186427B2 (ja) | 2017-08-23 |
Family
ID=48534472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501614A Active JP6186427B2 (ja) | 2012-03-19 | 2013-03-19 | 抗菌性ファージのカクテルを含む組成物及び細菌感染症を処置するためのその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9962419B2 (enExample) |
| EP (1) | EP2833899B1 (enExample) |
| JP (1) | JP6186427B2 (enExample) |
| CN (1) | CN104519893B (enExample) |
| AU (1) | AU2013235883B2 (enExample) |
| BR (1) | BR112014023321B1 (enExample) |
| CA (1) | CA2867418C (enExample) |
| DK (1) | DK2833899T3 (enExample) |
| ES (1) | ES2814024T3 (enExample) |
| PT (1) | PT2833899T (enExample) |
| RU (1) | RU2654596C2 (enExample) |
| SG (1) | SG11201405829WA (enExample) |
| WO (1) | WO2013141730A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2865383A1 (en) * | 2013-10-25 | 2015-04-29 | Pherecydes Pharma | Phage therapy of pseudomonas infections |
| WO2016066722A2 (en) * | 2014-10-28 | 2016-05-06 | Ian Humphery-Smith | Bacteriophage combinations for human or animal therapy |
| US10455983B2 (en) | 2015-09-10 | 2019-10-29 | Prince Castle LLC | Modular food holding system |
| US20170157186A1 (en) * | 2015-12-02 | 2017-06-08 | Smart Phage, Inc. | Phage to treat bacteria on skin |
| US11554158B2 (en) | 2016-04-13 | 2023-01-17 | Northeast Ohio Medical University | GPNMB compositions for treatment of skin wounds |
| US11672839B2 (en) | 2016-12-05 | 2023-06-13 | Technechnophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof |
| WO2018146437A1 (en) | 2017-02-13 | 2018-08-16 | Biocontrol Limited | Therapeutic bacteriophage compositions |
| WO2019050902A1 (en) * | 2017-09-05 | 2019-03-14 | Adaptive Phage Therapeutics, Inc. | METHODS OF DETERMINING THE SENSITIVITY PROFILE OF A BACTERIAL STRAIN TO A THERAPEUTIC COMPOSITION |
| IL274002B2 (en) * | 2017-10-19 | 2026-03-01 | Mona E Buice | A topical preparation for improved healing of open wounds |
| JP7247192B2 (ja) * | 2017-12-11 | 2023-03-28 | アダプティブ ファージ セラピューティクス， インコーポレイテッド | ファージ分注システム |
| US11654166B2 (en) | 2018-01-02 | 2023-05-23 | Armata Pharmaceuticals, Inc. | Therapeutic bacteriophage compositions for treating Staphylococcus infection |
| CN109082414B (zh) * | 2018-06-29 | 2020-11-13 | 浙江工业大学 | 一种金黄色葡萄球菌噬菌体及应用 |
| US11155606B2 (en) | 2018-07-24 | 2021-10-26 | Medimmune, Llc | Antibody directed against S. aureus clumping factor a (ClfA) |
| CN109730235A (zh) * | 2019-02-01 | 2019-05-10 | 珠海横琴普罗恩能医用食品有限公司 | 一种用于医用食品的防腐剂 |
| WO2020237044A1 (en) * | 2019-05-21 | 2020-11-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bacteriophages for the treatment of tuberculosis |
| WO2021222257A1 (en) | 2020-04-27 | 2021-11-04 | Armata Pharmaceuticals, Inc. | Bacteriophage compositions for treating pseudomonas infection |
| CN111643724B (zh) * | 2020-07-01 | 2022-01-28 | 南京大学 | 一种载有噬菌体和酸性成纤维细胞生长因子的水凝胶伤口敷料的制备方法及其应用 |
| WO2022013314A1 (en) | 2020-07-14 | 2022-01-20 | Biontech R&D (Austria) Gmbh | Bacteriophage cocktails and uses thereof |
| WO2022013318A1 (en) | 2020-07-14 | 2022-01-20 | Biontech R&D (Austria) Gmbh | New mosaic bacteriophages and uses thereof |
| CN112251439B (zh) * | 2020-10-26 | 2022-06-21 | 齐鲁师范学院 | 拟南芥高温诱导启动子pHTG1及其重组载体 |
| CN112301001B (zh) * | 2020-11-03 | 2022-10-14 | 华中农业大学 | 金黄色葡萄球菌噬菌体lsa2311及其应用 |
| CN113201458B (zh) * | 2020-12-21 | 2022-05-27 | 青岛诺安百特生物技术有限公司 | 一种提高噬菌体制剂稳定性的组合物及其应用 |
| US20240415904A1 (en) * | 2021-05-12 | 2024-12-19 | Biomx Ltd. | Staphylococcus bacteriophage and uses thereof |
| US20240277791A1 (en) * | 2021-06-11 | 2024-08-22 | Integrated Pharma Services, Llc | Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins |
| DE202022102100U1 (de) | 2022-04-20 | 2022-04-27 | Prabhakar Ramesh Bhandari | Synergistische antibiotische pharmazeutische Zusammensetzung zur Behandlung von Staphylococcus aureus-Infektionen |
| EP4626449A1 (en) * | 2022-11-28 | 2025-10-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Acinetobacter baumannii phages |
| WO2025104708A1 (en) | 2023-11-16 | 2025-05-22 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Method for determining the susceptibility of bacteria to bacteriophages |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09511397A (ja) | 1994-04-05 | 1997-11-18 | エクスポネンシャル バイオセラピーズ，インコーポレイテッド | 遺伝子型改変バクテリオファージによる抗菌治療 |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| US6138401A (en) | 1999-06-25 | 2000-10-31 | Duncan; Franklin R. | Fish hook remover |
| CN1643139A (zh) | 2002-03-25 | 2005-07-20 | 沃里克大学 | 抗菌剂 |
| US20050095222A1 (en) | 2003-10-29 | 2005-05-05 | Taro Suzuki | Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet |
| US8309077B2 (en) | 2004-11-02 | 2012-11-13 | Chr. Hansen A/S | Stabilized bacteriophage formulations |
| MX2007005279A (es) | 2004-11-02 | 2008-03-11 | Gangagen Life Sciences Inc | Composiciones de bacteriofagos. |
| WO2006063176A2 (en) | 2004-12-06 | 2006-06-15 | The Government Of The Usa As Representedtd By The Secretary Of The Dept Of Health And Human Services | Inhibition of biofilm formation using bacteriophage |
| CA2609357A1 (en) | 2005-05-26 | 2006-11-30 | Gangagen Life Sciences Inc. | Bacterial management in animal holding systems |
| EP3115054B1 (en) | 2009-02-06 | 2019-11-20 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Antibacterial phage, phage peptides and methods of use thereof |
| PT104837A (pt) | 2009-11-24 | 2011-05-24 | Technophage Investiga O E Desenvolvimento Em Biotecnologia S A | P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o |
| EP3443970B1 (en) * | 2010-09-17 | 2020-09-09 | Tecnifar-Indústria Técnica Farmacêutica, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
-
2013
- 2013-03-19 RU RU2014141941A patent/RU2654596C2/ru active
- 2013-03-19 ES ES13725496T patent/ES2814024T3/es active Active
- 2013-03-19 AU AU2013235883A patent/AU2013235883B2/en active Active
- 2013-03-19 DK DK13725496.7T patent/DK2833899T3/da active
- 2013-03-19 SG SG11201405829WA patent/SG11201405829WA/en unknown
- 2013-03-19 WO PCT/PT2013/000016 patent/WO2013141730A1/en not_active Ceased
- 2013-03-19 JP JP2015501614A patent/JP6186427B2/ja active Active
- 2013-03-19 CN CN201380022586.5A patent/CN104519893B/zh active Active
- 2013-03-19 US US14/385,828 patent/US9962419B2/en active Active
- 2013-03-19 CA CA2867418A patent/CA2867418C/en active Active
- 2013-03-19 PT PT137254967T patent/PT2833899T/pt unknown
- 2013-03-19 BR BR112014023321-7A patent/BR112014023321B1/pt active IP Right Grant
- 2013-03-19 EP EP13725496.7A patent/EP2833899B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014141941A (ru) | Композиции коктейля, содержащие антибактериальные фаги, и способы их применения | |
| Simon et al. | Medical honey for wound care—still the ‘latest resort’? | |
| Sarheed et al. | Antimicrobial dressings for improving wound healing | |
| Konop et al. | Certain aspects of silver and silver nanoparticles in wound care: a minireview | |
| Nagoba et al. | Acetic acid treatment of pseudomonal wound infections–a review | |
| Boroumand et al. | Clinical trials on silver nanoparticles for wound healing | |
| Dryden et al. | Hot topics in reactive oxygen therapy: Antimicrobial and immunological mechanisms, safety and clinical applications | |
| Kerihuel | Effect of activated charcoal dressings on healing outcomes of chronic wounds | |
| JP2015529643A (ja) | 物理的抗微生物方法 | |
| Edwards-Jones | Antimicrobial and barrier effects of silver against methicillin-resistant Staphylococcus aureus | |
| Gunjan et al. | A comparative study of the effect of different topical agents on burn wound infections | |
| Yahia et al. | Quantitative evaluation of diabetic foot wound healing using hydrogel nanosilver based dressing vs. traditional dressing: A prospective randomized control study | |
| Yabanoglu et al. | Assessment of the effectiveness of silver-coated dressing, chlorhexidine acetate (0.5%), citric acid (3%), and silver sulfadiazine (1%) for topical antibacterial effects against the multi-drug resistant Pseudomonas aeruginosa infecting full-skin thickness burn wounds on rats | |
| Ruiz-Tovar et al. | Total occlusive ionic silver-containing dressing vs mupirocin ointment application vs conventional dressing in elective colorectal surgery: effect on incisional surgical site infection | |
| Nagoba et al. | A simple and effective approach for the treatment of chronic wound infections caused by multiple antibiotic resistant Escherichia coli | |
| CN107921283A (zh) | 包括阿来西定的伤口护理产品 | |
| Nagoba et al. | Simple, effective and affordable approach for the treatment of burns infections | |
| CN105169455A (zh) | 一种烧烫伤外用急救医用敷料及其制备方法 | |
| Padilla et al. | Negative pressure wound therapy with instillation and dwell for the management of a complex burn: a case report and review of the literature | |
| US11202806B2 (en) | Amoeba therapeutic dressings, biomaterials, and solutions | |
| LaRiviere et al. | Silver toxicity with the use of silver-impregnated dressing and wound vacuum-assisted closure in an immunocompromised patient | |
| VI | Infection prophylaxis of gunshot wounds using probiotics | |
| EDWARDS | Use of SILVERCEL® NONADHERENT on burn wounds: A case series. | |
| Ivashchenko et al. | Use of Bacteriophages in the Treatment of Infected Wounds in Patients who have Allergy to Antibiotics | |
| Watts et al. | Evidence Summary: Wound management-low resource communities: citric acid as a topical antiseptic |